Search Results
Your search for ,ShE matches 5598 pages
Showing 351 - 400CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
Pinpointing Contributing Factors in Response to Posttransplant Donor Lymphocyte Infusion in Patients With AML
Researchers have identified factors that could determine whether donor lymphocyte infusion—a type of adoptive cell therapy—will result in remission among patients with acute myeloid leukemia (AML) who have relapsed following allogeneic hematopoietic stem cell transplant (HSCT), according to a...
New Findings on Aspirin and Risk of Colorectal Cancer Recurrence
According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurrence in patients with cancers that harbor a PI3K mutation. These mutations are common to many types ...
Some Patients With Low-Risk Ductal Carcinoma In Situ May Be Able to Avoid Surgery
Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy). After 2 years, the rate of invasive...
Getting a Lung Cancer Diagnosis Was Shocking
For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer
The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with...
Telephone-Based Therapy May Reduce Fatigue Interference With Functioning in Metastatic Breast Cancer Survivors
Telephone-delivered acceptance and commitment therapy may be effective in reducing the interference of fatigue with functioning and improving the quality of life among survivors of metastatic breast cancer, according to a recent study published by Mosher et al in the Journal of Clinical Oncology....
ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH, NCI
ASCO has applauded Monica M. Bertagnolli, MD, FASC, FASCO, for her service as the 17th Director of the National Institutes of Health (NIH) and Kimryn Rathmell, MD, PhD, for her work as the 17th Director of the National Cancer Institute (NCI). “ASCO would like to extend our deepest gratitude to Dr....
AACR Expresses Sincere Appreciation After NIH Director Monica M. Bertagnolli, MD, Steps Down
The American Association for Cancer Research (AACR) expressed its gratitude to Monica M. Bertagnolli, MD, for her outstanding service to the United States during her 14-month tenure as Director of the National Institutes of Health (NIH). Background Dr. Bertagnolli recently announced that she will...
Risks of Preterm Birth, Low Birth Weight, Birth Defects Among Children Born to Young Men With Cancer
The risk of having children who experience preterm birth and low birth weight—but not birth defects—may be increased among male adolescents and young adults with cancer, according to a recent study published by Murphy et al in the Journal of the National Cancer Institute. Background Prior research...
Monica Bertagnolli, MD, FACS, FASCO, Steps Down as NIH Director
On January 14, Monica Bertagnolli, MD, FACS, FASCO, announced that she was ending her tenure as the 17th Director of the National Institutes of Health (NIH). She began her role as Director on November 9, 2023. Dr. Bertagnolli was the 16th Director of the National Cancer Institute, a role she held...
Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality
Although lung cancer and related cancer deaths decreased in the world’s 10 most populous countries from 1990 to 2019, these positive statistics may not address trends in mortality linked to tobacco use, air pollution, and asbestos exposure, according to a recent study published by Jani et al in...
NCCN Joins International Meeting to Improve Cancer Care in the Middle East North Africa Region
The National Comprehensive Cancer Network (NCCN) announced that the organization participated in a 2-day meeting at the Middle East North Africa (MENA)–NCCN Regional Coordinating Center. Background The MENA-NCCN Regional Coordinating Center is supported by the Ministry of National Guard Health...
ORACLE Test May Predict Survival in Early Stages of Lung Cancer
The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors, according to a recent study published by Biswas et al in Nature Cancer. The findings could help physicians make more informed treatment decisions...
Adjuvant Tamoxifen Reduces 15-Year Risk of Recurrence in ‘Good Risk’ DCIS Without Radiation Therapy
Adjuvant tamoxifen was associated with a reduced risk of 15-year ipsilateral breast cancer recurrence as well as invasive ipsilateral breast cancer recurrence in patients with “good-risk” ductal carcinoma in situ (DCIS) who omitted radiation therapy after breast-conserving surgery, according to a...
Novel Tool for Predicting Response to Immunotherapy in Melanoma Under Study
A team of scientists from the United Kingdom and the United States has discovered that the activity of macrophages may prove to be useful in predicting whether or not a patient with melanoma will respond to immunotherapy. Their findings, published in JCO Oncology Advances, may help clinicians to...
OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer
For women with high-risk, BRCA-positive breast cancer, 1 year of adjuvant treatment with the PARP inhibitor olaparib following primary treatment continued to improve overall survival compared with placebo, according to the third interim analysis of the phase III OlympiA trial presented at the 2024...
Belinda Avalos, MD, Begins Term as 2025 ASH President
Belinda Avalos, MD, Professor of Medicine and a senior advisor to the President of Atrium Health Levine Cancer, will serve as president of the American Society of Hematology (ASH) for a year-long term through December 2025. Overview Dr. Avalos is a physician-scientist with a special clinical...
Addition of Palbociclib to Standard Therapy in Metastatic Hormone Receptor–Positive, HER2-Positive Breast Cancer
Addition of the CDK4/6 inhibitor palbociclib to the current standard of care for first-line maintenance therapy after induction chemotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival in patients with hormone receptor (HR)-positive,...
Role of Cancer Gene in Esophageal Adenocarcinoma May Support Paradigm Shift in Predicting Disease
A genetic mutation long believed to drive the development of esophageal cancer may play a protective role early in the disease, according to a recent study published by Ganguli et al in Nature Cancer. The findings could help physicians identify which patients are at greater risk of developing...
Glucarpidase May Improve Recovery Following Methotrexate-Induced Kidney Toxicity
The drug glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy agent methotrexate, according to a recent study published by Gupta et al in Blood. Background As a result of its ability to penetrate the blood-brain barrier, methotrexate is one of the most...
Risk-Reducing Surgeries Improve Survival for Younger Patients With Breast Cancer Who Are BRCA Carriers, Study Finds
Patients with early-onset breast cancer (aged 40 or younger at diagnosis) who have BRCA1 and/or BRCA2 pathogenic or likely pathogenic variants had improved overall survival by undergoing risk-reducing surgeries, including bilateral mastectomy and/or salpingo-oophorectomy, according to data...
Studies Point to the Role of Diet in Hematologic Malignancies
According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The speakers said their studies may ultimately lead to dietary interventions that could alter the course of ...
Patient With Ruxolitinib-Treated Myelofibrosis Who Develops Anemia
This is Part 2 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the management of a patient with myelofibrosis who develops...
Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment
Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, the role of this innovative treatment in advanced melanoma, and relevant data, peer-reviewed literature, and FDA approvals in 2024. She...
Influence of Social Networks Among Older Patients With Cancer
Researchers have received a $3.5 million grant from the National Cancer Institute to examine the impact of social networks on the decision-making process among older patients with cancer. Background Many individuals have social networks, which includes those who offer a connection and have similar...
ASCO Elects 2026–2027 President, Six New Members of Board of Directors, Nominating Committee
ASCO announced the election of Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, to lead as its President beginning in June 2026, as well as an additional six ASCO members to serve on its Board of Directors and Nominating Committee. 2026–2027 ASCO President-Elect Dr. Mittendorf, a long-time ASCO...
Second-Line Treatment of KRAS-Mutant Metastatic NSCLC
This is Part 2 of Clinical Perspectives on KRAS-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Gregory Riely, Rebecca Heist, and Joshua Sabari discuss the second-line treatment of a patient with KRAS-mutant...
CBD May Not Reduce Scan-Related Anxiety in Patients With Advanced Breast Cancer
Cannabidiol (CBD) may not significantly change scan-related anxiety compared with placebo in patients with advanced breast cancer but may result in lower overall anxiety levels, according to a recent study published by Nayak et al in JAMA Network Open. Background Anxiety is common among adult...
Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2-negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline plus taxane-based chemotherapy regimens compared with those...
Balancing Pain Management and Addiction Risks in Oncology
Managing cancer pain in patients with substance use disorder presents a unique challenge for oncologists, requiring a balance between effective symptom management and mitigation of the risks of substance misuse. During the 2024 JADPRO Live, Antonia Corrigan, MSN, ANP-C, ACHPN, emphasized the...
My Cancer Diagnosis and Renewed Commitment to Fight for Patients
Over 40 years ago, I lost my dear sister, Gale, to cancer. She left behind a beautiful 4-year-old daughter and a grieving family. Driven by this profound loss, I was determined to ensure that no other family would face that same heartbreak. That resoluteness led to the founding of Friends of...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients With ‘Good-Risk’ DCIS Who Forgo Radiation
For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the 2024 San Antonio Breast Cancer Symposium...
Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL
The addition of blinatumomab to chemotherapy may improve disease-free survival in pediatric patients newly diagnosed with National Cancer Institute (NCI) standard-risk B-cell acute lymphoblastic leukemia (ALL) at average or high risk of relapse, according to new findings presented by Rau et al at...
Quality of Life Similar Among Patients With Low-Risk DCIS Whether They Received Active Monitoring or Surgery
Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring and those who received upfront treatment reported comparable physical, emotional, and psychological outcomes, according to results from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium...
Tiffany Traina, MD, FASCO, on Advances in the Treatment of HR-Positive Breast Cancer
Tiffany Traina, MD, FASCO, is Vice Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where she has been a medical oncologist on the Breast Medicine Service since 2006. Dr. Traina is also the Section Head of the Triple Negative Breast Cancer Clinical Research Program. In ...
Fiber-Rich Diet May Help Prevent Complications After Stem Cell Transplant
Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease (GVHD) by cultivating a healthy gut microbiome, according to research presented by Paredes et al at the 2024 American Society of Hematology (ASH) Annual Meeting &...
Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL
A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated chronic lymphocytic leukemia (CLL) compared with one of two standard multidrug treatment regimens,...
Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease
Rachel E. Rau, MD, of Seattle Children’s Hospital, and Sumit Gupta, MD, PhD, of the Hospital for Sick Children in Toronto, review results from Children’s Oncology Group Study AALL1731, which assessed the addition of blinatumomab to chemotherapy in newly diagnosed childhood standard-risk B-cell...
Award Recipients Announced for the 2024 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor two researchers for their significant contributions to breast cancer research during the 2024 SABCS. 2024 AACR Distinguished Lectureship in Breast Cancer Research ...
The Lindy Effect and Open Cancer Surgery
The Lindy effect (also known as Lindy’s Law) is a theorized phenomenon by which the future life expectancy of some nonperishable thing, such as a technology or an idea, is proportional to its current age. Thus, the Lindy effect proposes the longer a period something has survived to exist or be used ...
Understanding How Stigma and Incorrect Physician Assumptions About LGBTQ+ Patients’ Needs Contribute to Medical Mistrust
Over the past decade, ASCO has focused its resources on advancing health equity for sexual and gender minority (SGM) individuals with cancer. In 2017, the Society published a position statement “Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations,” which...
Deciphering the Impact of the 2024 Election on Cancer Care
Two weeks after the 2024 election, the Presidency and 119th Congress are coming into focus, with nearly all races called. Republican Donald Trump was elected President, and Republicans regained control of the U.S. Senate (53–47) and maintained control in the House of Representatives (218–212 at...
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
IMF Welcomes Newly Elected Board of Directors Members
The International Myeloma Foundation (IMF) welcomes four of its newest members to the IMF Board of Directors: Director of Strategic Growth at Raanes & Oliver Capital Advisors, Kent Oliver; Managing Partner of Global Commercialization Strategy and Solutions at ZS Associates, Maria Whitman;...
ASH Announces Recipients of 2024 ASH Advocacy Awards
The American Society of Hematology (ASH) honored Rep. Michael Burgess, MD (R-TX) and Centers for Disease Control and Prevention (CDC) health scientist Mary Hulihan, DrPH, for their leadership on issues of importance to hematology research and practice at the 2024 ASH Annual Meeting &...
Understanding the Assessment and Treatment of High-Risk Myelofibrosis
At the 2024 JADPRO Live event, which is held annually for advanced practitioners in oncology, high-risk myelofibrosis was a featured topic. “The treatment landscape has developed so much that JADPRO asked us to present our talks on the main stage this year,” said Julie Huynh-Lu, PA-C, Supervisor...
AI and the Future of Lung Cancer Screening: Still Room for Improvement
“Artificial intelligence [AI] will be used in all aspects of [lung cancer] screening…, and it continues to get better,” commented topic overview speaker David F. Yankelevitz, MD, Professor of Radiology at the Icahn School of Medicine at Mount Sinai, New York, at the Quantitative Imaging Workshop...
